UBS Maintains Neutral on Sherwin-Williams, Raises Price Target to $350

UBS maintains Sherwin-Williams (NYSE:SHW) with a Neutral and raises the price target from $310 to $350.

byBenzinga Newsdesk

January 4, 2022

1 minute read

UBS maintains Sherwin-Williams (NYSE:SHW) with a Neutral and raises the price target from $310 to $350.

JP Morgan Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $50

By Benzinga Newsdesk

Today, 3:49 AM

JP Morgan analyst Cory Kasimov initiates coverage on Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Overweight rating and announces Price Target of $50.

CERE

IDEXX Laboratories Forecast 2023 EPS Of $9.27-$9.75, YoY Growth Of 16%-21% As Reported And 19%-26% On Comparable Basis, Versus Estimate Of $9.5

By Benzinga Newsdesk

Today, 3:49 AM

The company expects 2023 revenue of $3.59-$3.69 billion, reflecting reported growth of 6.5% - 9.5% and organic growth of 7% - 10%, compared to the consensus of $3.62 billion.

IDXX

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

By Bill Haddad

Today, 3:49 AM

Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.60) by 35 percent.

RAIN

Beacon Roofing Supply Q3 EPS $0.91 Misses $1.30 Estimate, Sales $1.87B Beat $1.81B Estimate

By Benzinga Newsdesk

Today, 3:49 AM

Beacon Roofing Supply (NASDAQ:BECN) reported quarterly earnings of $0.91 per share which missed the analyst consensus estimate of $1.30 by 30 percent. This is a 9.9 percent decrease over earnings of $1.01 per share from

BECN

UBS Maintains Neutral on Sherwin-Williams, Raises Price Target to $350

Related Posts

JP Morgan Initiates Coverage On Cerevel Therapeutics Hldg with Overweight Rating, Announces Price Target of $50

IDEXX Laboratories Forecast 2023 EPS Of $9.27-$9.75, YoY Growth Of 16%-21% As Reported And 19%-26% On Comparable Basis, Versus Estimate Of $9.5

Rain Therapeutics Q2 EPS $(0.39) Beats $(0.60) Estimate

Beacon Roofing Supply Q3 EPS $0.91 Misses $1.30 Estimate, Sales $1.87B Beat $1.81B Estimate